<DOC>
	<DOCNO>NCT02984995</DOCNO>
	<brief_summary>This Phase 2 , multi-center , open-label , single-arm study evaluate efficacy , safety pharmacokinetics quizartinib monotherapy Japanese subject FLT3-ITD positive refractory relapse acute myeloid leukemia .</brief_summary>
	<brief_title>Phase 2 Study Quizartinib Participants With Acute Myeloid Leukemia ( AML ) FLT3 Internal Tandem Duplication ( FLT3/ITD ) Mutation</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>AML patient first relapse refractory prior therapy Presence FLT3ITD activate mutation bone marrow peripheral blood Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( PS ) 0 2 Diagnosis acute promyelocytic leukemia AML secondary prior chemotherapy neoplasm . Persistent , clinically significant &gt; Grade 1 nonhematologic toxicity prior AML therapy Prior treatment FLT3 target therapy Active infection well control antibacterial , antifungal and/or antiviral therapy</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>FLT3-ITD</keyword>
	<keyword>Positive refractory relapse acute myeloid leukemia</keyword>
	<keyword>Hematology malignancy</keyword>
	<keyword>Developmental Phase II</keyword>
</DOC>